Search Results - "Ahmann, Greg J."

A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5 by White, Brian S., Lanc, Irena, O’Neal, Julie, Gupta, Harshath, Fulton, Robert S., Schmidt, Heather, Fronick, Catrina, Belter, Edward A., Fiala, Mark, King, Justin, Ahmann, Greg J., DeRome, Mary, Mardis, Elaine R., Vij, Ravi, DiPersio, John F., Levy, Joan, Auclair, Daniel, Tomasson, Michael H.

“…Multiple myeloma (MM) is a disease of copy number variants (CNVs), chromosomal translocations, and single-nucleotide variants (SNVs). To enable integrative…”
Get full text

Transcriptional profiles define drug refractory disease in myeloma by Zhu, Yuan Xiao, Bruins, Laura A., Chen, Xianfeng, Shi, Chang‐Xin, Bonolo De Campos, Cecilia, Meurice, Nathalie, Wang, Xuewei, Ahmann, Greg J., Ramsower, Colleen A., Braggio, Esteban, Rimsza, Lisa M., Stewart, A. Keith

“…Identifying biomarkers associated with disease progression and drug resistance are important for personalized care. We investigated the expression of 121…”
Get full text

Clinical implication of centrosome amplification in plasma cell neoplasm by Chng, Wee J., Ahmann, Greg J., Henderson, Kim, Santana-Davila, Rafael, Greipp, Philip R., Gertz, Morie A., Lacy, Martha Q., Dispenzieri, Angela, Kumar, Shaji, Rajkumar, S. Vincent, Lust, John A., Kyle, Robert A., Zeldenrust, Steven R., Hayman, Suzanne R., Fonseca, Rafael

“…The mechanisms underlying aneuploidy in multiple myeloma (MM) are unclear. Centrosome amplification has been implicated as the cause of chromosomal instability…”
Get full text

Measles, rubella, and mumps titers post chemotherapy plus autologous stem cell transplant in multiple myeloma patients by Arribas, Mariano, Ahmann, Greg J., Buckner Petty, Skye, Braggio, Esteban, Theel, Elitza S., Fonseca, Rafael

Get full text

Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity by Sebastian, Sinto, Zhu, Yuan X., Braggio, Esteban, Shi, Chang-Xin, Panchabhai, Sonali C., Van Wier, Scott A., Ahmann, Greg J., Chesi, Marta, Bergsagel, P.Leif, Stewart, A.Keith, Fonseca, Rafael

“…Lenalidomide is an immunomodulatory drug (IMiDs) with clinical efficacy in multiple myeloma (MM) and other late B-cell neoplasms. Although cereblon (CRBN) is…”
Get full text

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy by Gertz, Morie A., Lacy, Martha Q., Dispenzieri, Angela, Greipp, Philip R., Litzow, Mark R., Henderson, Kimberly J., Van Wier, Scott A., Ahmann, Greg J., Fonseca, Rafael

“…Fluorescence in situ hybridization (FISH) is more sensitive than conventional cytogenetics for recognizing chromosomal changes. Several FISH-detected…”
Get full text

“Direct to Drug” screening as a precision medicine tool in multiple myeloma by Bonolo de Campos, Cecilia, Meurice, Nathalie, Petit, Joachim L., Polito, Alysia N., Zhu, Yuan Xiao, Wang, Panwen, Bruins, Laura A., Wang, Xuewei, Lopez Armenta, Ilsel D., Darvish, Susie A., Ahmann, Greg J., Henderson, Kimberly J., Tian, Shulan, Kruse, Jonas J., Stewart, William M., Larsen, Jeremy T., Reeder, Craig B., Dingli, David, Kapoor, Prashant, Kumar, Shaji K., Fonseca, Rafael, Bergsagel, P. Leif, Braggio, Esteban, Stewart, A. Keith

“…Seventy-six FDA-approved oncology drugs and emerging therapeutics were evaluated in 25 multiple myeloma (MM) and 15 non-Hodgkin’s lymphoma cell lines and in…”
Get full text

Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone by Kumar, Shaji K., Uno, Hajime, Jacobus, Susanna J., Wier, Scott A. Van, Ahmann, Greg J., Henderson, Kimberly J., Callander, Natalie S., Haug, Jessica L., Siegel, David S., Greipp, Philip R., Fonseca, Rafael, Rajkumar, S. Vincent

“…Detection of specific chromosomal abnormalities by FISH and metaphase cytogenetics allows risk stratification in multiple myeloma; however, gene expression…”
Get full text

Prevalence of BCL-2/J(H) Translocation in Healthy African Americans by Colon-Otero, Gerardo, Van Wier, Scott A., Ahmann, Greg J., Braggio, Esteban, Albertie, Monica L., Weis, Jennifer A., Ailawadhi, Sikander, Cerhan, James R., Vishnu, Prakash, Jorgensen, Matthew S., Foran, James M., Thomas, Colleen S., Fonseca, Rafael

“…The translocation t(14;18)(q32;q21) (BCL-2/J(H)) is present in over 80 % of all follicular lymphomas and is detectable in peripheral blood lymphocytes (PBL) of…”
Get full text

Impact of high‐risk classification by FISH: an Eastern Cooperative Oncology Group (ECOG) study E4A03 by Jacobus, Susanna J., Kumar, Shaji, Uno, Hajime, Van Wier, Scott A., Ahmann, Greg J., Henderson, Kimberly J., Callander, Natalie S., Williams, Michael E., Siegel, David S., Greipp, Philip R., Rajkumar, S. Vincent, Fonseca, Rafael

“…Summary Lenalidomide with dexamethasone is a standard induction treatment regimen for newly diagnosed myeloma (although a Federal Drug Administration…”
Get full text

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy by Lohr, Jens G., Stojanov, Petar, Carter, Scott L., Cruz-Gordillo, Peter, Lawrence, Michael S., Auclair, Daniel, Sougnez, Carrie, Knoechel, Birgit, Gould, Joshua, Saksena, Gordon, Cibulskis, Kristian, McKenna, Aaron, Chapman, Michael A., Straussman, Ravid, Levy, Joan, Perkins, Louise M., Keats, Jonathan J., Schumacher, Steven E., Rosenberg, Mara, Anderson, Kenneth C., Richardson, Paul, Krishnan, Amrita, Lonial, Sagar, Kaufman, Jonathan, Siegel, David S., Vesole, David H., Roy, Vivek, Rivera, Candido E., Rajkumar, S. Vincent, Kumar, Shaji, Fonseca, Rafael, Ahmann, Greg J., Bergsagel, P. Leif, Stewart, A. Keith, Hofmeister, Craig C., Efebera, Yvonne A., Jagannath, Sundar, Chari, Ajai, Trudel, Suzanne, Reece, Donna, Wolf, Jeffrey, Martin, Thomas, Zimmerman, Todd, Rosenbaum, Cara, Jakubowiak, Andrzej J., Lebovic, Daniel, Vij, Ravi, Stockerl-Goldstein, Keith, Getz, Gad, Golub, Todd R.

“…We performed massively parallel sequencing of paired tumor/normal samples from 203 multiple myeloma (MM) patients and identified significantly mutated genes…”
Get full text

IAP antagonists induce anti-tumor immunity in multiple myeloma by Chesi, Marta, Mirza, Noweeda N, Garbitt, Victoria M, Sharik, Meaghen E, Dueck, Amylou C, Asmann, Yan W, Akhmetzyanova, Ilseyar, Kosiorek, Heidi E, Calcinotto, Arianna, Riggs, Daniel L, Keane, Niamh, Ahmann, Gregory J, Morrison, Kevin M, Fonseca, Rafael, Lacy, Martha Q, Dingli, David, Kumar, Shaji K, Ailawadhi, Sikander, Dispenzieri, Angela, Buadi, Francis, Gertz, Morie A, Reeder, Craig B, Lin, Yi, Chanan-Khan, Asher A, Stewart, A Keith, Fooksman, David, Bergsagel, P Leif

“…Blockade of cIAP1 and cIAP2 induces a tumor cell-autonomous type-I IFN response that activates myeloid cells and potentiates anti-tumor immunity in…”
Get full text

Ex vivo sensitivity to venetoclax is predictive of clinical activity by Bonolo de Campos, Cecilia, Meurice, Nathalie, Bruins, Laura A., Petit, Joachim L., Polito, Alysia N., Wang, Xuewei, Zhu, Yuan Xiao, Shi, Chang-Xin, Ahmann, Greg J., Braggio, Esteban, Stewart, Keith

Get full text

Multiple myeloma cells' capacity to decompose H 2 O 2 determines lenalidomide sensitivity by Sebastian, Sinto, Zhu, Yuan X, Braggio, Esteban, Shi, Chang-Xin, Panchabhai, Sonali C, Van Wier, Scott A, Ahmann, Greg J, Chesi, Marta, Bergsagel, P Leif, Stewart, A Keith, Fonseca, Rafael

“…Lenalidomide is an immunomodulatory drug (IMiDs) with clinical efficacy in multiple myeloma (MM) and other late B-cell neoplasms. Although cereblon ( ) is an…”
Get full text